Introduction
The field of cancer chemoprevention has developed considerably over the past two decades with several large randomised trials having been undertaken. Some of these have been positive and have included a demonstration of the efficacy of tamoxifen to reduce the risk of breast cancer [1] and finasteride to have an impact on prostate cancer incidence. [2] Unfortunately several trials have been negative and some have even produced results suggesting a deleterious effect of the agent under investigation. [3] Chemoprevention trials are, of necessity, usually very large and extremely costly. To date, one of the main methods for choosing agents to investigate in trials has been retrospective population-based analysis of an apparent association between ingestion of the agent and a reduced incidence of cancer. Unfortunately such analyses are often flawed by many sources of bias. In addition, adverse effects of exposure to such agents over a protracted period have not been anticipated. Successful chemoprevention requires an agent which has a significant impact on cancer risk but is also extremely safe and well tolerated. With the increasing understanding of molecular mechanisms leading to carcinogenesis, it is imperative that cancer preventive agents are developed more rationally and are targeted towards these mechanisms -both to increase efficacy and also to reduce the potential for toxicity. This article will highlight some of the more promising potential targets which can be used to choose and design drugs for testing as chemopreventive agents. The identification of targets could also enable the development of biomarkers to test efficacy during early clinical development.
Molecular targets for chemopreventive agents
Phenotypic and genotypic alterations occur during carcinogenesis and lead to the features which define a malignant cell. One of these involves abnormalities in the survival pathways which enable malignant cells to avoid apoptosis. Among the best described survival pathways are those involving the growth factor receptor (GFR)/Ras/Mitogen Activated Protein Kinase (MAPK) pathway, [4] phophotidylinositol-3-kinase (PI3K)/protein kinase B(Akt) [5] and signal H:/WPS/Molecular targets for chemoprevention: role in choosing and developing new agents 160407 1 transducers and activators of transcription (STATs) [6] or nuclear factor κB(NF-κB). [7] Signalling through the GFR/Ras/MAPK pathway is central to 
Cell cycle regulation
One of the hallmarks of malignancy is a loss of regulation of cell cycle progression. Several proteins have been identified which regulate progression through the cell cycle and a group of molecules, the cyclins and cyclin-dependent kinases have been extensively investigated in recent years. Cyclin D1 is a ratelimiting factor in progression of cells through the G1 phase of the cell cycle. [8] Its over expression is associated with carcinogenesis -particularly in breast and H:/WPS/Molecular targets for chemoprevention: role in choosing and developing new agents 160407 prostate cancer. Another target protein involved with cell cycle progression is activator protein-1 (AP-1). [9] A 
Growth factor signalling pathways

Cyclo-oxygenase 2 (COX-2)
The cycloxygenases (COX-1 and COX-2) have been an increasing focus as targets for chemopreventive drug development. [10] These enzymes are responsible for converting arachadonic acid into prostatglandins. COX-2 is 
